Pharmaceutical manufacturers spend on average $1 billion developing a product for commercialization. With this tremendous investment, it is a pharmaceutical developer’s nightmare to have its product fail during the New Drug Application (NDA) filing process due to safety concerns or lack of pharmacovigilance systems…
Michael O’Gorman, CEO, Sentrx. Sentrx provides pharmacovigilance outsourcing service. For more information, visit sentrx.com.